Aartsma-Rus A - Search Results

1

Non-sequential and multi-step splicing of the dystrophin transcript.

Gazzoli I, Pulyakhina I, Verwey NE, Ariyurek Y, Laros JF, 't Hoen PA, Aartsma-Rus A. Gazzoli I, et al. RNA Biol. 2016;13(3):290-305. doi: 10.1080/15476286.2015.1125074. Epub 2015 Dec 15. RNA Biol. 2016. PMID: 26670121 Free PMC article.

2

Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy.

't Hoen PA, van der Wees CG, Aartsma-Rus A, Turk R, Goyenvalle A, Danos O, Garcia L, van Ommen GJ, den Dunnen JT, van Deutekom JC. 't Hoen PA, et al. Pharmacogenomics. 2006 Apr;7(3):281-97. doi: 10.2217/14622416.7.3.281. Pharmacogenomics. 2006. PMID: 16610940

3

Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides.

Aartsma-Rus A, Janson AA, Heemskerk JA, De Winter CL, Van Ommen GJ, Van Deutekom JC. Aartsma-Rus A, et al. Ann N Y Acad Sci. 2006 Oct;1082:74-6. doi: 10.1196/annals.1348.058. Ann N Y Acad Sci. 2006. PMID: 17145928

4

Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.

Aartsma-Rus A, van Ommen GJ. Aartsma-Rus A, et al. RNA. 2007 Oct;13(10):1609-24. doi: 10.1261/rna.653607. Epub 2007 Aug 7. RNA. 2007. PMID: 17684229 Free PMC article. Review.

5

Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.

Aartsma-Rus A, van Vliet L, Hirschi M, Janson AA, Heemskerk H, de Winter CL, de Kimpe S, van Deutekom JC, 't Hoen PA, van Ommen GJ. Aartsma-Rus A, et al. Mol Ther. 2009 Mar;17(3):548-53. doi: 10.1038/mt.2008.205. Epub 2008 Sep 23. Mol Ther. 2009. PMID: 18813282 Free PMC article.

6

A 3 months mild functional test regime does not affect disease parameters in young mdx mice.

van Putten M, de Winter C, van Roon-Mom W, van Ommen GJ, 't Hoen PA, Aartsma-Rus A. van Putten M, et al. Neuromuscul Disord. 2010 Apr;20(4):273-80. doi: 10.1016/j.nmd.2010.02.004. Epub 2010 Mar 21. Neuromuscul Disord. 2010. PMID: 20307983

7

Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.

Aartsma-Rus A, Houlleberghs H, van Deutekom JC, van Ommen GJ, 't Hoen PA. Aartsma-Rus A, et al. Oligonucleotides. 2010 Apr;20(2):69-77. doi: 10.1089/oli.2009.0215. Oligonucleotides. 2010. PMID: 20377429

8

Accurate quantification of dystrophin mRNA and exon skipping levels in duchenne muscular dystrophy.

Spitali P, Heemskerk H, Vossen RH, Ferlini A, den Dunnen JT, 't Hoen PA, Aartsma-Rus A. Spitali P, et al. Lab Invest. 2010 Sep;90(9):1396-402. doi: 10.1038/labinvest.2010.98. Epub 2010 May 10. Lab Invest. 2010. PMID: 20458276 Free article.

9

Antisense-mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy.

Aartsma-Rus A. Aartsma-Rus A. RNA Biol. 2010 Jul-Aug;7(4):453-61. doi: 10.4161/rna.7.4.12264. Epub 2010 Jul 1. RNA Biol. 2010. PMID: 20523110 Review.

10

BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model.

Shi S, Hoogaars WM, de Gorter DJ, van Heiningen SH, Lin HY, Hong CC, Kemaladewi DU, Aartsma-Rus A, ten Dijke P, 't Hoen PA. Shi S, et al. Neurobiol Dis. 2011 Feb;41(2):353-60. doi: 10.1016/j.nbd.2010.10.003. Epub 2010 Oct 16. Neurobiol Dis. 2011. PMID: 20940052 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

257 results

Search Page

Filters